The peptide network regulated by angiotensin converting enzyme (ACE) in hematopoiesis

Cell Cycle

Volumn 10, Issue 9, 2011, Pages 1363-1369

  Shen, Xiao Z ^a   Bernstein, Kenneth E ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

Ac SDKP; Angiotensin 1 7; Angiotensin converting enzyme (ACE); Angiotensin II; AT1 receptor; Hematopoiesis; Myelopoiesis; Reninangiotensin system (RAS); Substance P

Indexed keywords

ACETIC ACID DERIVATIVE; ACETYL SERINEASPARTATELYSINEPROLINE; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN II; ANGIOTENSIN[1-7]; DIPEPTIDYL CARBOXYPEPTIDASE; SUBSTANCE P; UNCLASSIFIED DRUG;

BLOOD CELL; BONE MARROW CELL; CELL DIFFERENTIATION; CELL LINEAGE; ENZYME ACTIVITY; HEMATOPOIESIS; HUMAN; NONHUMAN; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; STRESS;

EID: 79955626581     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.10.9.15444     Document Type: Review

References (77)

1. Corvol P, Williams TA, Soubrier F. Peptidyl dipeptidase A: angiotensin I-converting enzyme. Methods Enzymol 1995; 248:283-305.
2. Cushman DW, Cheung HS, Sabo EF, Ondetti MA. Design of potent competitive inhibitors of angiotensin-converting enzyme. Carboxyalkanoyl and mercaptoalkanoyl amino acids. Biochemistry 1977; 16:5484-91.
3. Skidgel RA, Erdös EG. Angiotensin I converting enzyme. Adv Exp Med Biol 1989; 247:25-8.
4. Hemming ML, Selkoe DJ. Amyloid beta-protein is degraded by cellular angiotensin-converting enzyme (ACE) and elevated by an ACE inhibitor. J Biol Chem 2005; 280:37644-50. (Pubitemid 41642372)
5. Harmer D, Gilbert M, Borman R, Clark KL. Quantitative mRNA expression profiling of ACE 2, a novel homologue of angiotensin converting enzyme. FEBS Lett 2002; 532:107-10. (Pubitemid 35375876)
6. Ryan US, Ryan JW, Whitaker C, Chiu A. Localization of angiotensin converting enzyme (kininase II). II. Immunocytochemistry and immunofluorescence. Tissue Cell 1976; 8:125-45.
7. Rivière G. Angiotensin-converting enzyme: a protein conserved during evolution. J Soc Biol 2009; 203:281-93.
8. Lindpaintner K, Ganten D. The cardiac renin-angiotensin system. An appraisal of present experimental and clinical evidence. Circ Res 1991; 68:905-21.
9. Paul M, Bachmann J, Ganten D. The tissue renin-angiotensin systems in cardiovascular disease. Trends Cardiovasc Med 1992; 2:94-9.
10. Zhu D, Shi J, Zhang Y, Wang B, Liu W, Chen Z, et al. Central Angiotensin II Stimulation Promotes β Amyloid Production in Sprague Dawley Rats. PLoS One 2011; 6:16037.
11. Navar LG, Prieto MC, Satou R, Kobori H. Intrarenal angiotensin II and its contribution to the genesis of chronic hypertension. Curr Opin Pharmacol 2011.
12. Yasue S, Masuzaki H, Okada S, Ishii T, Kozuka C, Tanaka T, et al. Adipose tissue-specific regulation of angiotensinogen in obese humans and mice: impact of nutritional status and adipocyte hypertrophy. Am J Hypertens 2010; 23:425-31.
13. Hubert C, Savary K, Gasc JM, Corvol P. The hematopoietic system: a new niche for the renin-angiotensin system. Nat Clin Pract Cardiovasc Med 2006; 3:80-5. (Pubitemid 43203376)
14. Haznedaroglu IC, Tuncer S, Gürsoy M. A local renin-angiotensin system in the bone marrow. Med Hypotheses 1996; 46:507-10. (Pubitemid 26184769)
15. Moore RN, Osmand AP, Dunn JA, Joshi JG, Rouse BT. Substance P augmentation of CSF-1-stimulated in vitro myelopoiesis. A two-signal progenitor restricted, tuftsin-like effect. J Immunol 1988; 141:2699-703. (Pubitemid 18263056)
16. Lenfant M, Wdzieczak-Bakala J, Guittet E, Prome JC, Sotty D, Frindel E. Inhibitor of hematopoietic pluripotent stem cell proliferation: purification and determination of its structure. Proc Natl Acad Sci USA 1989; 86:779-82. (Pubitemid 19056239)
17. Rodgers K, Xiong S, DiZerega GS. Effect of angiotensin II and angiotensin(1-7) on hematopoietic recovery after intravenous chemotherapy. Cancer Chemother Pharmacol 2003; 51:97-106.
18. Park TS, Zambidis ET. A role for the renin-angiotensin system in hematopoiesis. Haematologica 2009; 94:745-7.
19. Vlahakos DV, Marathias KP, Madias NE. The role of the renin-angiotensin system in the regulation of erythropoiesis. Am J Kidney Dis 2010; 56:558-65.
20. Lam BS, Adams GB. Hematopoietic stem cell lodgment in the adult bone marrow stem cell niche. Int J Lab Hematol 2010; 32:551-8.
21. Strawn WB, Richmond RS, Ann Tallant E, Gallagher PE, Ferrario CM. Renin-angiotensin system expression in rat bone marrow haematopoietic and stromal cells. Br J Haematol 2004; 126:120-6. (Pubitemid 38859492)
22. Rodgers KE, Xiong S, Steer R, diZerega GS. Effect of angiotensin II on hematopoietic progenitor cell proliferation. Stem Cells 2000; 18:287-94.
23. Zambidis ET, Park TS, Yu W, Tam A, Levine M, Yuan X, et al. Expression of angiotensin-converting enzyme (CD143) identifies and regulates primitive hemangioblasts derived from human pluripotent stem cells. Blood 2008; 112:3601-14.
24. Lin C, Datta V, Okwan-Duodu D, Chen X, Fuchs S, Alsabeh R, et al. Angiotensin-converting enzyme is required for normal myelopoiesis. FASEB J 2010.
25. Tsubakimoto Y, Yamada H, Yokoi H, Kishida S, Takata H, Kawahito H, et al. Bone marrow angiotensin AT1 receptor regulates differentiation of monocyte lineage progenitors from hematopoietic stem cells. Arterioscler Thromb Vasc Biol 2009; 29:1529-36.
26. Rodgers KE, Xiong S, diZerega GS. Accelerated recovery from irradiation injury by angiotensin peptides. Cancer Chemother Pharmacol 2002; 49:403-11.
27. Nahmod KA, Vermeulen ME, Raiden S, Salamone G, Gamberale R, Fernández-Calotti P, et al. Control of dendritic cell differentiation by angiotensin II. FASEB J 2003; 17:491-3.
28. Nahmod K, Gentilini C, Vermeulen M, Uharek L, Wang Y, Zhang J, et al. Impaired function of dendritic cells deficient in angiotensin II type 1 receptors. J Pharmacol Exp Ther 2010; 334:854-62.
29. Nahmod KA, Geffner JR, Walther T. Angiotensin II type 1a-deficient bone marrow-derived dendritic cells produce higher levels of monocyte chemoattractant protein 1. Hypertension 2010; 56:6-7.
30. Shao J, Nangaku M, Miyata T, Inagi R, Yamada K, Kurokawa K, et al. Imbalance of T-cell subsets in angiotensin II-infused hypertensive rats with kidney injury. Hypertension 2003; 42:31-8. (Pubitemid 36842233)
31. Platten M, Youssef S, Hur EM, Ho PP, Han MH, Lanz TV, et al. Blocking angiotensin-converting enzyme induces potent regulatory T cells and modulates TH1- and TH17-mediated autoimmunity. Proc Natl Acad Sci USA 2009; 106:14948-53.
32. Pennefather JN, Lecci A, Candenas ML, Patak E, Pinto FM, Maggi CA. Tachykinins and tachykinin receptors: a growing family. Life Sci 2004; 74:1445-63. (Pubitemid 38077208)
33. Fernández-Dueñas V, Ciruela F, Gandía J, Sánchez S, Planas E, Poveda R. Histamine H3 receptor activation potentiates peripheral opioid-mediated antinociception: substance P role in peripheral inflammation in mice. Eur J Pharmacol 2010; 638:72-7.
34. Rameshwar P, Poddar A, Gascón P. Hematopoietic regulation mediated by interactions among the neurokinins and cytokines. Leuk Lymphoma 1997; 28:1-10. (Pubitemid 28067573)
35. Skidgel RA, Erdös EG. Angiotensin converting enzyme (ACE) and neprilysin hydrolyze neuropeptides: a brief history, the beginning and follow-ups to early studies. Peptides 2004; 25:521-5. (Pubitemid 38591559)
36. Rameshwar P, Gascón P. Substance P (SP) mediates production of stem cell factor and interleukin-1 in bone marrow stroma: potential autoregulatory role for these cytokines in SP receptor expression and induction. Blood 1995; 86:482-90.
37. Maggio JE. Tachykinins. Annu Rev Neurosci 1988; 11:13-28.
38. Nowicki M, Ostalska-Nowicka D, Kondraciuk B, Miskowiak B. The significance of substance P in physiological and malignant haematopoiesis. J Clin Pathol 2007; 60:749-55. (Pubitemid 47056902)
39. Rameshwar P, Ganea D, Gascón P. In vitro stimulatory effect of substance P on hematopoiesis. Blood 1993; 81:391-8.
40. Guarini S, Bazzani C, Tagliavini S, Bertolini A, Ferrari W. Capsaicin prevents the adrenocorticotropin- induced improvement of cardiovascular function and survival in hemorrhage-shocked rats. Neurosci Lett 1992; 143:181-4.
41. Qian J, Ramroop K, McLeod A, Bandari P, Livingston DH, Harrison JS, et al. Induction of hypoxia-inducible factor-1alpha and activation of caspase- 3 in hypoxia-reoxygenated bone marrow stroma is negatively regulated by the delayed production of substance P. J Immunol 2001; 167:4600-8. (Pubitemid 32954340)
42. Calvo CF, Chavanel G, Senik A. Substance P enhances IL-2 expression in activated human T cells. J Immunol 1992; 148:3498-504.
43. Sirinek LP, O'Dorisio MS. Modulation of immune function by intestinal neuropeptides. Acta Oncol 1991; 30:509-17.
44. Payan DG, Brewster DR, Missirian-Bastian A, Goetzl EJ. Substance P recognition by a subset of human T lymphocytes. J Clin Invest 1984; 74:1532-9. (Pubitemid 15200249)
45. Grassin-Delyle S, Buenestado A, Vallat L, Naline E, Marx S, Decocq J, et al. Expression and proliferative effect of hemokinin-1 in human B-cells. Peptides 2011; In press.
46. Rameshwar P, Gascon P, Ganea D. Stimulation of IL-2 production in murine lymphocytes by substance P and related tachykinins. J Immunol 1993; 151:2484-96. (Pubitemid 23264501)
47. Rossdeutsch A, Smart N, Riley PR. Thymosin beta4 and Ac-SDKP: tools to mend a broken heart. J Mol Med 2008; 86:29-35.
48. Rieger KJ, Saez-Servent N, Papet MP, Wdzieczak- Bakala J, Morgat JL, Thierry J, et al. Involvement of human plasma angiotensin I-converting enzyme in the degradation of the haemoregulatory peptide N-acetyl-seryl-aspartyl-lysyl- proline. Biochem J 1993; 296:373-8. (Pubitemid 23350839)
49. Azizi M, Rousseau A, Ezan E, Guyene TT, Michelet S, Grognet JM, et al. Acute angiotensin-converting enzyme inhibition increases the plasma level of the natural stem cell regulator N-acetyl-seryl-aspartyllysyl- proline. J Clin Invest 1996; 97:839-44. (Pubitemid 26060543)
50. Sosne G, Qiu P, Goldstein AL, Wheater M. Biological activities of thymosin beta4 defined by active sites in short peptide sequences. FASEB J 2010; 24:2144-51.
51. Huang WQ, Wang QR. Expression of Thymosin beta4 in Murine Bone Marrow Endothelial Cells, HL-60 Cells and Human Peripheral Blood Mononuclear Cells. Zhongguo Shi Yan Xue Ye Xue Za Zhi 2001; 9:10-3.
52. Huang WQ, Wang QR. Bone marrow endothelial cells secrete thymosin beta4 and AcSDKP. Exp Hematol 2001; 29:12-8. (Pubitemid 32054762)
53. Bonnet D, Lemoine FM, Pontvert-Delucq S, Baillou C, Najman A, Guigon M. Direct and reversible inhibitory effect of the tetrapeptide acetyl-N-Ser- Asp-Lys-Pro (Seraspenide) on the growth of human CD34+ subpopulations in response to growth factors. Blood 1993; 82:3307-14. (Pubitemid 23356700)
54. Bonnet D, Lemoine FM, Khoury E, Pradelles P, Najman A, Guigon M. Reversible inhibitory effects and absence of toxicity of the tetrapeptide acetyl- N-Ser-Asp-Lys-Pro (AcSDKP) in human long-term bone marrow culture. Exp Hematol 1992; 20:1165-9.
55. 125I-labeled Hpp-Aca-SDKP in rat cardiac fibroblasts. Am J Physiol Heart Circ Physiol 2007; 292:984-93.
56. Coutton C, Guigon M, Bohbot A, Ferrani K, Oberling F. Photoprotection of normal human hematopoietic progenitors by the tetrapeptide N-AcSDKP. Exp Hematol 1994; 22:1076-80. (Pubitemid 24314773)
57. Watanabe T, Brown GS, Kelsey LS, Yan Y, Jackson JD, Ewel C, et al. In vivo protective effects of tetrapeptide AcSDKP, with or without granulocyte colony-stimulation factor, on murine progenitor cells after sublethal irradiation. Exp Hematol 1996; 24:713-21.
58. Deeg HJ, Seidel K, Hong DS, Yu C, Huss R, Schuening FG, et al. In vivo radioprotective effect of AcSDKP on canine myelopoiesis. Ann Hematol 1997; 74:117-22.
59. Massé A, Ramirez LH, Bindoula G, Grillon C, Wdzieczak-Bakala J, Raddassi K, et al. The tetrapeptide acetyl-N-Ser-Asp-Lys-Pro (Goralatide) protects from doxorubicin-induced toxicity: improvement in mice survival and protection of bone marrow stem cells and progenitors. Blood 1998; 91:441-9. (Pubitemid 28053365)
60. Fuchs S, Xiao HD, Cole JM, Adams JW, Frenzel K, Michaud A, et al. Role of the N-terminal catalytic domain of angiotensin-converting enzyme investigated by targeted inactivation in mice. J Biol Chem 2004; 279:15946-53. (Pubitemid 38509282)
61. Bernstein KE, Shen XZ, Gonzalez-Villalobos RA, Billet S, Okwan-Duodu D, Ong FS, et al. Different in vivo functions of the two catalytic domains of angiotensin-converting enzyme (ACE). Curr Opin Pharmacol 2010.
62. Niedermeyer J, Kriz M, Hilberg F, Garin-Chesa P, Bamberger U, Lenter MC, et al. Targeted disruption of mouse fibroblast activation protein. Mol Cell Biol 2000; 20:1089-94. (Pubitemid 30044246)
63. Di Daniel E, Glover CP, Grot E, Chan MK, Sanderson TH, White JH, et al. Prolyl oligopeptidase binds to GAP-43 and functions without its peptidase activity. Mol Cell Neurosci 2009; 41:373-82.
64. Varagic J, Trask AJ, Jessup JA, Chappell MC, Ferrario CM. New angiotensins. J Mol Med 2008; 86:663-71.
65. Yamada K, Iyer SN, Chappell MC, Ganten D, Ferrario CM. Converting enzyme determines plasma clearance of angiotensin-(1-7). Hypertension 1998; 32:496-502.
66. Santos RA, Simoes e Silva AC, Maric C, Silva DM, Machado RP, de Buhr I, et al. Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas. Proc Natl Acad Sci USA 2003; 100:8258-63.
67. Villar AJ, Pedersen RA. Parental imprinting of the Mas protooncogene in mouse. Nat Genet 1994; 8:373-9. (Pubitemid 24375604)
68. Metzger R, Bader M, Ludwig T, Berberich C, Bunnemann B, Ganten D. Expression of the mouse and rat mas proto-oncogene in the brain and peripheral tissues. FEBS Lett 1995; 357:27-32.
69. Kostenis E, Milligan G, Christopoulos A, Sanchez- Ferrer CF, Heringer-Walther S, Sexton PM, et al. G-protein-coupled receptor Mas is a physiological antagonist of the angiotensin II type 1 receptor. Circulation 2005; 111:1806-13. (Pubitemid 40525146)
70. Heringer-Walther S, Eckert K, Schumacher SM, Uharek L, Wulf-Goldenberg A, Gembardt F, et al. Angiotensin-(1-7) stimulates hematopoietic progenitor cells in vitro and in vivo. Haematologica 2009; 94:857-60.
71. Ellefson DD, diZerega GS, Espinoza T, Roda N, Maldonado S, Rodgers KE. Synergistic effects of coadministration of angiotensin 1-7 and Neupogen on hematopoietic recovery in mice. Cancer Chemother Pharmacol 2004; 53:15-24.
72. Savary K, Michaud A, Favier J, Larger E, Corvol P, Gasc JM. Role of the renin-angiotensin system in primitive erythropoiesis in the chick embryo. Blood 2005; 105:103-10. (Pubitemid 40053070)
73. Jokubaitis VJ, Sinka L, Driessen R, Whitty G, Haylock DN, Bertoncello I, et al. Angiotensinconverting enzyme (CD143) marks hematopoietic stem cells in human embryonic, fetal and adult hematopoietic tissues. Blood 2008; 111:4055-63.
74. Tavian M, Biasch K, Sinka L, Vallet J, Péault B. Embryonic origin of human hematopoiesis. Int J Dev Biol 2010; 54:1061-5.
75. Chisi JE, Briscoe CV, Ezan E, Genet R, Riches AC, Wdzieczak-Bakala J. Captopril inhibits in vitro and in vivo the proliferation of primitive haematopoietic cells induced into cell cycle by cytotoxic drug administration or irradiation but has no effect on myeloid leukaemia cell proliferation. Br J Haematol 2000; 109:563-70. (Pubitemid 30415183)
76. Charrier S, Michaud A, Badaoui S, Giroux S, Ezan E, Sainteny F, et al. Inhibition of angiotensin I-converting enzyme induces radioprotection by preserving murine hematopoietic short-term reconstituting cells. Blood 2004; 104:978-85. (Pubitemid 39038016)
77. Davis TA, Landauer MR, Mog SR, Barshishat- Kupper M, Zins SR, Amare MF, et al. Timing of captopril administration determines radiation protection or radiation sensitization in a murine model of total body irradiation. Exp Hematol 2010; 38:270-81.